Open AccessComprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
Author(s) -
Romero Atocha,
JantusLewintre Eloisa,
GarcíaPeláez Beatriz,
Royuela Ana,
Insa Amelia,
Cruz Patricia,
Collazo Ana,
Pérez Altozano Javier,
Vidal Oscar Juan,
Diz Pilar,
Cobo Manuel,
Hernández Berta,
Vázquez Estevez Sergio,
Benítez Gretel,
Guirado Maria,
Majem Margarita,
Bernabé Reyes,
Ortega Ana Laura,
Blasco Ana,
BoschBarrera Joaquim,
Jurado Jose M.,
García González Jorge,
Viteri Santiago,
Garcia Giron Carlos,
Massutí Bartomeu,
Lopez Martín Ana,
RodriguezFesta Alejandro,
CalabuigFariñas Silvia,
MolinaVila Miguel Ángel,
Provencio Mariano
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12832
Subject(s) - intraclass correlation , medicine , t790m , oncology , reproducibility , osimertinib , bioinformatics , epidermal growth factor receptor , erlotinib , cancer , biology , gefitinib , clinical psychology , statistics , mathematics , psychometrics
Plasma samples from 72 EGFR ‐mutant advanced NSCLC patients, collected upon progression to first‐line TKI, were analyzed by seven methodologies (two NGS‐based methods, three high‐sensitivity PCR‐based platforms, and two FDA‐approved methods). Our study demonstrates a good to excellent agreement between methodologies and supports the use of liquid biopsies for therapy decision‐making.